Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection.

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

Vanderbilt's Wenhan Zhu, PhD, has received a three-year award from the G. Harold and Leila Y. Mathers Foundation to support his research that aims to answer a fundamental question about bacterial physiology and engineer probiotics to improve gut inflammatory diseases.

Vanderbilt researchers have discovered another acid resistance mechanism for UTI-causing E. coli, laying the foundation for targeted antibacterial therapies.

Understanding how hellbenders — large, fully aquatic salamanders — fight fungal pathogens and disease is important for protecting these unique stream predators; Vanderbilt researchers add new insights.

A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.

Vanderbilt University Medical Center is set to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms.